10x Genomics, Inc. (TXG) Stock & Financials
Data as of (545 days ago)|Source: SEC EDGAR
10x Genomics, Inc. (TXG) is a life sciences tools & services company. The company reports annual revenue of $611M and net loss of $183M. Its profit margin is -29.9%.
What to check next
For informational purposes only. Not investment advice. Data may be delayed or inaccurate; verify independently. The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results. Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing.
10x Genomics, Inc. Key Financials(TTM Est.)
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
10x Genomics, Inc. Financial Health ScoreFY2025
Below average; significant concerns in multiple areas
+19 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026
About 10x Genomics, Inc.
- Industry
- Life Sciences Tools & Services
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Thin Marginsvs 14.4% sector median / 7.5% avg
Currently operating at a loss of 30 cents per dollar of revenue.
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profit margin 500% below sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026
10x Genomics, Inc. 9-Year Revenue, Profit & Cash Flow History
Revenue has grown at a 31.7% CAGR over the past 8 years.
Annual Financials
FY2025 - FY2017| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $642.8M(+5.2%) | $610.8M(-1.3%) | $618.7M(+19.8%) | $516.4M(+5.3%) | $490.5M(+64.1%) | $298.8M(+457.8%) | $53.6M(-63.4%) | $146.3M(+105.8%) | $71.1M |
| Net Income | $-43,544,000(+76.2%) | $-182,627,000(+28.4%) | $-255,099,000(-53.7%) | $-166,000,000(-185.1%) | $-58,223,000(+89.3%) | $-542,731,000(-1636.7%) | $-31,251,000(+72.2%) | $-112,485,000(-499.5%) | $-18,762,000 |
| Total Assets | $1.0B | $918.6M | $965.1M | $1.0B | $1.0B | $929.3M | $605.9M | $124.3M | - |
| Total Debt | - | - | - | - | - | $0 | $29.7M | $25.5M | - |
| Total Equity | $796.3M | $710.1M | $741.0M | $805.7M | $817.6M | $739.1M | $420.1M | $-219,987,000 | $-112,509,000 |
| Profit Margin | -6.8% | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% | -58.3% | -76.9% | -26.4% |
| ROE | -5.5% | -25.7% | -34.4% | -20.6% | -7.1% | -73.4% | -7.4% | - | - |
| ROA | -4.2% | -19.9% | -26.4% | -16.1% | -5.7% | -58.4% | -5.2% | -90.5% | - |
Quarterly Financials
Last 8 quarters| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $149.0M | $172.9M | $154.9M | $151.7M | $153.1M | $141.0M | $153.6M | $146.8M |
| Net Income | $-27,472,000 | $34.5M | $-34,358,000 | $-35,753,000 | $-37,897,000 | $-59,949,000 | $-92,986,000 | $-62,414,000 |
| Total Assets | $1.0B | $980.0M | $903.4M | $937.8M | $929.7M | $922.9M | $948.5M | $989.6M |
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
10x Genomics, Inc. Free Cash Flow & Dividend Coverage
Cash Flow History
FY2017 - FY2025| Metric | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating CF | -$10.7M | -$76.4M | $34.6M | -$217.9M | -$21.4M | -$33.6M | -$15.2M | $6.7M | $136.1M |
| CapEx | -$3.8M | -$6.3M | -$42.7M | -$36.7M | -$101.3M | -$131.7M | -$48.6M | -$12.4M | -$5.9M |
| Free Cash Flow | -$14.5M | -$82.7M | -$8.1M | -$254.6M | -$122.7M | -$165.3M | -$63.8M | -$5.7M | $130.1M |
| FCF Margin | -20.3% | - | -15.2% | -85.2% | -25.0% | -32.0% | -10.3% | -0.9% | 20.2% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026
10x Genomics, Inc. Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for TXG.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
10x Genomics, Inc. FAQ
What is 10x Genomics, Inc.'s annual revenue?
10x Genomics, Inc. (TXG) reported $611 million in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is 10x Genomics, Inc. profitable?
10x Genomics, Inc. reported a net loss with a -29.9% profit margin, totaling $183 million in net losses (TTM). All figures from SEC EDGAR 10-K filings.
Does 10x Genomics, Inc. pay dividends?
No, 10x Genomics, Inc. (TXG) does not currently pay dividends to shareholders.
What is 10x Genomics, Inc.'s financial health score?
10x Genomics, Inc. has a financial health score of 55/100 (Grade: D), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of 10x Genomics, Inc. financial data are available?
9 years of financial data are available for 10x Genomics, Inc. from FY2017 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.